Edwards Lifesciences Corp (EW) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Edwards Lifesciences Corp stock (EW) is currently trading at $82.67. Edwards Lifesciences Corp PE ratio is 45.67. Edwards Lifesciences Corp PS ratio (Price-to-Sales) is 7.91. Analyst consensus price target for EW is $96.85. WallStSmart rates EW as Hold.
- EW PE ratio analysis and historical PE chart
- EW PS ratio (Price-to-Sales) history and trend
- EW intrinsic value — DCF, Graham Number, EPV models
- EW stock price prediction 2025 2026 2027 2028 2029 2030
- EW fair value vs current price
- EW insider transactions and insider buying
- Is EW undervalued or overvalued?
- Edwards Lifesciences Corp financial analysis — revenue, earnings, cash flow
- EW Piotroski F-Score and Altman Z-Score
- EW analyst price target and Smart Rating
Edwards Lifesciences Corp
📊 No data available
Try selecting a different time range
EW Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Edwards Lifesciences Corp (EW)
EW trades 544% above its Graham fair value of $12.31, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Edwards Lifesciences Corp (EW) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, profit margin. Concerns around eps growth. Fundamentals are solid but monitor weak areas for improvement.
Edwards Lifesciences Corp (EW) Key Strengths (4)
91.56% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $24 kept per $100 revenue
Strong profitability: $18 kept per $100 revenue
Supporting Valuation Data
Edwards Lifesciences Corp (EW) Areas to Watch (6)
Earnings declining -76.60%, profits shrinking
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 7.9x annual revenue
Premium pricing at 4.6x book value
Moderate profitability with room for improvement
Solid revenue growth at 13.30% per year
Supporting Valuation Data
Edwards Lifesciences Corp (EW) Detailed Analysis Report
Overall Assessment
This company scores 55/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Operating Margin. Profitability is solid with Operating Margin at 23.70%, Profit Margin at 17.70%.
The Bear Case
The primary concerns are EPS Growth, PEG Ratio, Price/Sales. Some valuation metrics including PEG Ratio (2.13), Price/Sales (7.91), Price/Book (4.63) suggest expensive pricing. Growth concerns include Revenue Growth at 13.30%, EPS Growth at -76.60%, which may limit upside. Profitability pressure is visible in Return on Equity at 10.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 10.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 13.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (EPS Growth, PEG Ratio). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EW Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EW's Price-to-Sales ratio of 7.91x trades at a deep discount to its historical average of 30.8x (1th percentile). The current valuation is 86% below its historical high of 54.58x set in Apr 2010, and 1% above its historical low of 7.83x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Edwards Lifesciences Corp (EW) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Edwards Lifesciences Corp is a mature, profitable business with steady cash generation. Revenue reached 6.1B with 13% growth year-over-year. Profit margins of 17.7% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 354M in free cash flow and 451M in operating cash flow. Earnings are translating into actual cash generation.
Earnings fell 77% YoY while revenue grew 13%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Edwards Lifesciences Corp.
Bottom Line
Edwards Lifesciences Corp is a well-established business delivering consistent profitability with 17.7% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Edwards Lifesciences Corp(EW)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.